Last updated: 2026-09-30 21:34:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
CalciMedica, Inc. (CALC) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $1,63, with a market capitalization of $11,47M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,58 to $36,00. This page covers its latest market performance, valuation, price trends and company information.
$11,47M | |
$1,67 | |
$2.807,00 | |
$1,58 | |
$1,61 | |
36,52K | |
77,77K | |
-- | |
$36,00 | |
$1,58 | |
-- | |
-- |
CalciMedica, Inc. (CALC) is trading at $1,59 in after-hours trading as of 2026-09-30 21:20:00, down 1,55% ($0,03) from the regular-session close of $1,61.
After-hours trading shows how investors are pricing CALC after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, CalciMedica, Inc. (CALC) moved from $1,86 to $1,63, representing a decline of 12,63% ($0,24).
The stock traded between $1,58 and $1,98 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 54,75 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 0,1%
CALC is currently trading at $1,63, placing it 0,1% of the way from its 52-week low of $1,58 to its 52-week high of $36,00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of CalciMedica, Inc. (CALC) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.